Psychiatry MMC

Case Report:
Phenobarbital-Induced Bullous Lesions in a Non-Comatose Patient
by Michael Keng, BS; Maritza Lagos, MD; Michael R. Liepman, MD; and Kimberly Trever, DO
In the Clinic:
One Holy Grail: Evidence- and Measurement-Based Practice
by John Greist, MD

Original Research:
Time to Response in Panic Disorder in a Naturalistic Setting: Combination Therapy with Alprazolam Orally Disintegrating Tablets and Serotonin Reuptake Inhibitors Compared to Serotonin Reuptake Inhibitors Alone
by David J. Katzelnick, MD; Johnaqa Saidi, MD; Mark R. Vanelli, MD, MHS; James W. Jefferson, MD; James M. Harper, PhD; and Kay E. McCrary, PharmD

Time to Response in Generalized Anxiety Disorder in a Naturalistic Setting: Combination Therapy with Alprazolam Orally Disintegrating Tablets and Serotonin Reuptake Inhibitors Compared to Serotonin Reuptake Inhibitors Alone
by Mark Hyman Rapaport, MD; Steve B. Skarky, MD; David J. Katzelnick, MD; Jeffrey N. DeWester, MD; James M. Harper, PhD; and Kay E. McCrary, PharmD
Research to Practice:
When Common Clinical Practice Meets Evidence-Based Medicine
by David Feifel, MD, PhD

Review:
Integrating Spiritual Assessment into a Psychiatric Inpatient Unit
by Michael D. McGee, MD; Jennifer Torosian, MSN
Trend Watch:
Generic Conversion of the SSRI Market and the Impact on Branded Products
by Elisa F. Cascade and Amir H. Kalali, MD

Expert Commentary: Generic Conversion of the SSRI Market and the Impact on Branded Products
by David V. Sheehan, MD, MBA